Rahway, New Jersey-based Merck & Co., Inc. (MRK) is an international healthcare company that offers human health pharmaceuticals across various areas, including Keytruda, Keytruda Qlex, Welireg, ...

Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...

Merck & Co. Inc. (NYSE:MRK) is one of the best low risk stocks to buy in 2026. On May 18, Merck announced that its pivotal ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.

Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds Merck & ...

Facility consolidates biosafety testing, analytical development, and cell bank manufacturing services into single building New rapid test offering with Blazar ® CHO Animal Origin Free (AOF) delivers ...

As Merck looks for growth opportunities ahead of Keytruda’s tumble over the patent cliff, the company’s future now looks a bit brighter in the glow of two late-stage trial wins for cancer drug Welireg ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company’s common stock ...

Merck & Co. has posted phase 2 data on zilovertamab vedotin in lymphoma, providing more evidence of the narrow safety and efficacy window that is open to the ROR1-directed antibody-drug conjugate (ADC ...

Unlock your investing potential with TipRanks Premium - Now At 40% OFF! Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter The latest update is out from Merck & ...